234 related articles for article (PubMed ID: 15141021)
1. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
Gouazé V; Yu JY; Bleicher RJ; Han TY; Liu YY; Wang H; Gottesman MM; Bitterman A; Giuliano AE; Cabot MC
Mol Cancer Ther; 2004 May; 3(5):633-9. PubMed ID: 15141021
[TBL] [Abstract][Full Text] [Related]
2. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
[TBL] [Abstract][Full Text] [Related]
3. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
4. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
5. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells.
Liu YY; Han TY; Giuliano AE; Cabot MC
J Biol Chem; 1999 Jan; 274(2):1140-6. PubMed ID: 9873062
[TBL] [Abstract][Full Text] [Related]
6. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.
Gouazé-Andersson V; Yu JY; Kreitenberg AJ; Bielawska A; Giuliano AE; Cabot MC
Biochim Biophys Acta; 2007 Dec; 1771(12):1407-17. PubMed ID: 18035065
[TBL] [Abstract][Full Text] [Related]
7. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs.
Osborn MT; Chambers TC
J Biol Chem; 1996 Nov; 271(48):30950-5. PubMed ID: 8940082
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of glucosylceramides in multidrug-resistant cancer cells.
Lavie Y; Cao H; Bursten SL; Giuliano AE; Cabot MC
J Biol Chem; 1996 Aug; 271(32):19530-6. PubMed ID: 8702646
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Shabbits JA; Mayer LD
Mol Cancer Ther; 2002 Jan; 1(3):205-13. PubMed ID: 12467215
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
Norris-Cervetto E; Callaghan R; Platt FM; Dwek RA; Butters TD
J Biol Chem; 2004 Sep; 279(39):40412-8. PubMed ID: 15263008
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.
Uchiyama-Kokubu N; Watanabe T
Anticancer Drugs; 2001 Oct; 12(9):769-79. PubMed ID: 11593059
[TBL] [Abstract][Full Text] [Related]
13. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
Chao CC
FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
15. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
16. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.
Lavie Y; Cao Ht; Volner A; Lucci A; Han TY; Geffen V; Giuliano AE; Cabot MC
J Biol Chem; 1997 Jan; 272(3):1682-7. PubMed ID: 8999846
[TBL] [Abstract][Full Text] [Related]
17. Ceramide glycosylation potentiates cellular multidrug resistance.
Liu YY; Han TY; Giuliano AE; Cabot MC
FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
[TBL] [Abstract][Full Text] [Related]
18. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
[TBL] [Abstract][Full Text] [Related]
19. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells.
Sun YL; Zhou GY; Li KN; Gao P; Zhang QH; Zhen JH; Bai YH; Zhang XF
Neoplasma; 2006; 53(1):1-8. PubMed ID: 16416005
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
